Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing topline Phase 2 clinical study results for Tedopi®, with details on study design, efficacy endpoints, and upcoming presentation/webcast. It contains no financial statements or regulatory filings, no request for shareholder votes, no management changes, no dividend, no M&A. It is not an earnings release (no revenue or profit figures), nor an investor presentation/slides, nor a quarterly/interim report. Therefore it falls into the miscellaneous Regulatory Filings category (RNS) as a general corporate announcement.
2026-05-22 French
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
Regulatory Filings Classification · 85% confidence The document is a press release announcing clinical trial topline results and upcoming presentation/webcast dates. It contains no financial statements, no executive certifications, no shareholder votes, no merger or financing details, and no substantive reporting content. It is a general corporate/regulatory announcement about clinical data, fitting the fallback category for miscellaneous regulatory communications.
2026-05-22 English
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Major Shareholding Notification Classification · 95% confidence The document is a notification from OSE Immunotherapeutics about the total number of voting rights and shares composing the capital as of April 30, 2026. It references specific legal articles related to disclosure of share capital and voting rights. The content is focused on informing shareholders about the capital structure and voting rights, not on financial performance, management changes, or other report types. The document length is 2368 characters, which is relatively short and consistent with a formal announcement rather than a full report. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes or status of significant share ownership or voting rights. Therefore, the appropriate classification is MRQ with high confidence.
2026-05-06 French
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial communication from OSE Immunotherapeutics presenting consolidated unaudited financial results for the fiscal year 2025 and cash position as of Q1 2026. It includes comprehensive financial data such as revenues, expenses, net results, cash flows, and strategic outlook. The text mentions that the audited consolidated accounts and the Universal Registration Document for 2025 will be filed by May 28, 2026, indicating this is a preliminary financial report. The document is lengthy (over 13,000 characters) and contains substantive financial data and analysis, not just an announcement or certification. It is not a full annual report (10-K equivalent) since it is unaudited and preliminary, but it is a comprehensive financial report for a full fiscal year. This fits the definition of an Interim / Quarterly Report (IR) because it is a comprehensive financial report for a period shorter than a full fiscal year or a preliminary report for a full year before audit completion. However, since it covers the full fiscal year 2025 results (albeit unaudited) and some Q1 2026 cash position, it is more aligned with an Interim / Quarterly Report (IR) rather than a full Annual Report (10-K) or an Earnings Release (ER) which is usually shorter and less detailed. It is not an Audit Report (AR) because the audit is not completed. It is not a Regulatory Filing (RNS) because it contains detailed financial data, not just a certification or announcement. Therefore, the best classification is Interim / Quarterly Report (IR) with high confidence. FY 2025
2026-04-30 French
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
Annual Report Classification · 95% confidence The document is a detailed report of OSE Immunotherapeutics' full year 2025 unaudited consolidated financial results, including comprehensive financial data such as revenues, expenses, net income, cash flows, and cash position. It also discusses the company's cash runway, financing plans, and audit status. The presence of detailed financial statements and analysis for a full fiscal year, along with management commentary on financial performance and outlook, clearly identifies this as an Annual Report type document. The document is not merely an announcement or a press release about the report's publication but contains substantive financial data and management discussion. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2026-04-30 English
OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque
Regulatory Filings Classification · 55% confidence The document is a corporate press release announcing that OSE Immunotherapeutics’ partner Veloxis Pharmaceuticals received orphan drug designation from the U.S. FDA for pegrizeprument (VEL-101). It does not present financial results, regulatory filings like an annual or quarterly report, nor management changes, share transactions, dividends, or proxy materials. It is a general corporate announcement of a regulatory milestone. There is no specific filing category for orphan drug designations, so the appropriate category is the fallback 'Regulatory Filings' (RNS).
2026-04-27 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.